APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Drug based on PARP Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cancer Drug based on PARP Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026184 pages

Choose your research edition.

Industry ResearchCancer Drug based on PARP Inhibitor Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Drug based on PARP Inhibitor Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Cancer Drug based on PARP Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Drug based on PARP Inhibitor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Drug based on PARP Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cancer Drug based on PARP Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cancer Drug based on PARP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Drug based on PARP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Drug based on PARP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cancer Drug based on PARP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Drug based on PARP Inhibitor include Clovis Oncology, Zai Lab, AstraZeneca, GSK, Pfizer and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Drug based on PARP Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Drug based on PARP Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Drug based on PARP Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Drug based on PARP Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Drug based on PARP Inhibitor Segment by Company

Clovis Oncology

Zai Lab

AstraZeneca

GSK

Pfizer

Merck & Co

Cancer Drug based on PARP Inhibitor Segment by Type

Talzenna

Rubraca

Zejula

Lynparza

Cancer Drug based on PARP Inhibitor Segment by Application

Ovarian Cancer

Breast Cancer

Other

Cancer Drug based on PARP Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Drug based on PARP Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Drug based on PARP Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Drug based on PARP Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Drug based on PARP Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Drug based on PARP Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cancer Drug based on PARP Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cancer Drug based on PARP Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cancer Drug based on PARP Inhibitor Industry Trends Table 2. Cancer Drug based on PARP Inhibitor Industry Drivers Table 3. Cancer Drug based on PARP Inhibitor Industry Opportunities and Challenges Table 4. Cancer Drug based on PARP Inhibitor Industry Restraints Table 5. Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturers Table 9. Global Cancer Drug based on PARP Inhibitor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Cancer Drug based on PARP Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cancer Drug based on PARP Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cancer Drug based on PARP Inhibitor Manufacturers, Product Type & Application Table 13. Global Cancer Drug based on PARP Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Drug based on PARP Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Talzenna Table 17. Major Manufacturers of Rubraca Table 18. Major Manufacturers of Zejula Table 19. Major Manufacturers of Lynparza Table 20. Global Cancer Drug based on PARP Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Cancer Drug based on PARP Inhibitor Sales by Type (2021-2026) & (K Units) Table 22. Global Cancer Drug based on PARP Inhibitor Sales by Type (2027-2032) & (K Units) Table 23. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2021-2026) Table 24. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2027-2032) Table 25. Global Cancer Drug based on PARP Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2026) & (K Units) Table 27. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2027-2032) & (K Units) Table 28. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2021-2026) Table 29. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Ovarian Cancer Table 31. Major Manufacturers of Breast Cancer Table 32. Major Manufacturers of Other Table 33. Global Cancer Drug based on PARP Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Cancer Drug based on PARP Inhibitor Sales by Application (2021-2026) & (K Units) Table 35. Global Cancer Drug based on PARP Inhibitor Sales by Application (2027-2032) & (K Units) Table 36. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2021-2026) Table 37. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2027-2032) Table 38. Global Cancer Drug based on PARP Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2026) & (K Units) Table 40. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2027-2032) & (K Units) Table 41. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2021-2026) Table 42. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2027-2032) Table 43. Global Cancer Drug based on PARP Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Cancer Drug based on PARP Inhibitor Sales by Region (2021-2026) & (K Units) Table 45. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2021-2026) Table 46. Global Cancer Drug based on PARP Inhibitor Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Cancer Drug based on PARP Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Cancer Drug based on PARP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 50. North America Cancer Drug based on PARP Inhibitor Sales by Country (2027-2032) & (K Units) Table 51. Europe Cancer Drug based on PARP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 53. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Cancer Drug based on PARP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2027-2032) & (K Units) Table 60. Global Cancer Drug based on PARP Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2021-2026) Table 64. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2027-2032) Table 65. Clovis Oncology Company Information Table 66. Clovis Oncology Business Overview Table 67. Clovis Oncology Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolio Table 69. Clovis Oncology Recent Development Table 70. Zai Lab Company Information Table 71. Zai Lab Business Overview Table 72. Zai Lab Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolio Table 74. Zai Lab Recent Development Table 75. AstraZeneca Company Information Table 76. AstraZeneca Business Overview Table 77. AstraZeneca Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolio Table 79. AstraZeneca Recent Development Table 80. GSK Company Information Table 81. GSK Business Overview Table 82. GSK Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. GSK Cancer Drug based on PARP Inhibitor Product Portfolio Table 84. GSK Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Pfizer Cancer Drug based on PARP Inhibitor Product Portfolio Table 89. Pfizer Recent Development Table 90. Merck & Co Company Information Table 91. Merck & Co Business Overview Table 92. Merck & Co Cancer Drug based on PARP Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolio Table 94. Merck & Co Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Cancer Drug based on PARP Inhibitor Distributors List Table 98. Cancer Drug based on PARP Inhibitor Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Cancer Drug based on PARP Inhibitor Product Image Figure 2. Global Cancer Drug based on PARP Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Drug based on PARP Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Drug based on PARP Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global Cancer Drug based on PARP Inhibitor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cancer Drug based on PARP Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Talzenna Image Figure 9. Rubraca Image Figure 10. Zejula Image Figure 11. Lynparza Image Figure 12. Global Cancer Drug based on PARP Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Cancer Drug based on PARP Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2021-2032) Figure 15. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Cancer Drug based on PARP Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2021-2032) Figure 18. Ovarian Cancer Image Figure 19. Breast Cancer Image Figure 20. Other Image Figure 21. Global Cancer Drug based on PARP Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Cancer Drug based on PARP Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2021-2032) Figure 24. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Cancer Drug based on PARP Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2021-2032) Figure 27. North America Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2021-2032) Figure 29. U.S. Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2021-2032) Figure 34. Germany Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2021-2032) Figure 41. China Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Market Share by Country (2021-2032) Figure 49. Brazil Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Cancer Drug based on PARP Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Cancer Drug based on PARP Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Figure 60. North America Cancer Drug based on PARP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Figure 62. Europe Cancer Drug based on PARP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Cancer Drug based on PARP Inhibitor Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Cancer Drug based on PARP Inhibitor Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Talzenna
  • Rubraca
  • Zejula
  • Lynparza
Applications
  • Ovarian Cancer
  • Breast Cancer
  • Other
Companies covered
  • Clovis Oncology
  • Zai Lab
  • AstraZeneca
  • GSK
  • Pfizer
  • Merck & Co

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Drug based on PARP Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Drug based on PARP Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cancer Drug based on PARP Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cancer Drug based on PARP Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cancer Drug based on PARP Inhibitor Market Dynamics
  1. 2.1 Cancer Drug based on PARP Inhibitor Industry Trends
  2. 2.2 Cancer Drug based on PARP Inhibitor Industry Drivers
  3. 2.3 Cancer Drug based on PARP Inhibitor Industry Opportunities and Challenges
  4. 2.4 Cancer Drug based on PARP Inhibitor Industry Restraints
3 Cancer Drug based on PARP Inhibitor Market by Manufacturers
  1. 3.1 Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cancer Drug based on PARP Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cancer Drug based on PARP Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Drug based on PARP Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cancer Drug based on PARP Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global Cancer Drug based on PARP Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Drug based on PARP Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Drug based on PARP Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Drug based on PARP Inhibitor Tier 1, Tier 2, and Tier 3
4 Cancer Drug based on PARP Inhibitor Market by Type
  1. 4.1 Cancer Drug based on PARP Inhibitor Type Introduction
  2. 4.1.1 Talzenna
  3. 4.1.2 Rubraca
  4. 4.1.3 Zejula
  5. 4.1.4 Lynparza
  6. 4.2 Global Cancer Drug based on PARP Inhibitor Sales by Type
  7. 4.2.1 Global Cancer Drug based on PARP Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Cancer Drug based on PARP Inhibitor Sales by Type (2021-2032)
  9. 4.2.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2021-2032)
  10. 4.3 Global Cancer Drug based on PARP Inhibitor Revenue by Type
  11. 4.3.1 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Cancer Drug based on PARP Inhibitor Revenue by Type (2021-2032)
  13. 4.3.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2021-2032)
5 Cancer Drug based on PARP Inhibitor Market by Application
  1. 5.1 Cancer Drug based on PARP Inhibitor Application Introduction
  2. 5.1.1 Ovarian Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Other
  5. 5.2 Global Cancer Drug based on PARP Inhibitor Sales by Application
  6. 5.2.1 Global Cancer Drug based on PARP Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Drug based on PARP Inhibitor Sales by Application (2021-2032)
  8. 5.2.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2021-2032)
  9. 5.3 Global Cancer Drug based on PARP Inhibitor Revenue by Application
  10. 5.3.1 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Drug based on PARP Inhibitor Revenue by Application (2021-2032)
  12. 5.3.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2021-2032)
6 Global Cancer Drug based on PARP Inhibitor Sales by Region
  1. 6.1 Global Cancer Drug based on PARP Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Drug based on PARP Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Drug based on PARP Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global Cancer Drug based on PARP Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Drug based on PARP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cancer Drug based on PARP Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cancer Drug based on PARP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cancer Drug based on PARP Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cancer Drug based on PARP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cancer Drug based on PARP Inhibitor Revenue by Region
  1. 7.1 Global Cancer Drug based on PARP Inhibitor Revenue by Region
  2. 7.1.1 Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cancer Drug based on PARP Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America Cancer Drug based on PARP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cancer Drug based on PARP Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe Cancer Drug based on PARP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cancer Drug based on PARP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Clovis Oncology
  2. 8.1.1 Clovis Oncology Company Information
  3. 8.1.2 Clovis Oncology Business Overview
  4. 8.1.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Portfolio
  6. 8.1.5 Clovis Oncology Recent Developments
  7. 8.2 Zai Lab
  8. 8.2.1 Zai Lab Company Information
  9. 8.2.2 Zai Lab Business Overview
  10. 8.2.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zai Lab Cancer Drug based on PARP Inhibitor Product Portfolio
  12. 8.2.5 Zai Lab Recent Developments
  13. 8.3 AstraZeneca
  14. 8.3.1 AstraZeneca Company Information
  15. 8.3.2 AstraZeneca Business Overview
  16. 8.3.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Cancer Drug based on PARP Inhibitor Product Portfolio
  18. 8.3.5 AstraZeneca Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Cancer Drug based on PARP Inhibitor Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Cancer Drug based on PARP Inhibitor Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Merck & Co
  32. 8.6.1 Merck & Co Company Information
  33. 8.6.2 Merck & Co Business Overview
  34. 8.6.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co Cancer Drug based on PARP Inhibitor Product Portfolio
  36. 8.6.5 Merck & Co Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Drug based on PARP Inhibitor Value Chain Analysis
  2. 9.1.1 Cancer Drug based on PARP Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Drug based on PARP Inhibitor Production Mode & Process
  6. 9.2 Cancer Drug based on PARP Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Drug based on PARP Inhibitor Distributors
  9. 9.2.3 Cancer Drug based on PARP Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst